Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. In advanced setting and after progression to imatinib, the multi-targeted receptor tyrosine kinase inhibitor sunitinib has clearly demonstrated a clinical benefit in terms of response rate and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulet-Margalef, Nuria, Garcia-del-Muro, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5171199/
https://www.ncbi.nlm.nih.gov/pubmed/28008275
http://dx.doi.org/10.2147/OTT.S101385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5171199/
https://www.ncbi.nlm.nih.gov/pubmed/28008275
http://dx.doi.org/10.2147/OTT.S101385

Ejemplares similares